eBC and mBC Treatment | KISQALI (ribociclib)
WEBLearn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI. See full Prescribing & Safety Info.
WEBKISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor...
Kisqali: Package Insert - Drugs.com
WEBAug 5, 2024 · Kisqali package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
FDA approves Kisqali and Kisqali Femara Co-Pack
WEB5 days ago · On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack,...
WEBWhat is KISQALI FEMARA CO-PACK? • KISQALI FEMARA CO-PACK is a prescription medicine used as the first hormonal-based therapy to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).
WEBKISQALI is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative advanced or metastatic breast cancer in...
KISQALI FEMARA Co-Pack | KISQALI® (ribociclib) | HCP
WEBThe KISQALI FEMARA Co-Pack is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
WEBKisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women
WEBKISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated as initial endocrine-based therapy for the treatment...
Frequently Asked Questions | KISQALI® (ribociclib)
WEBThe KISQALI FEMARA Co-Pack contains 2 different types of medicines: The violet tablet contains the medicine KISQALI. The yellow tablet contains the medicine FEMARA. It is not known if KISQALI or the KISQALI FEMARA Co-Pack are safe and effective in children.